



ASX ANNOUNCEMENT

Lumos Advances FebriDx® Sales with iMedical Purchase Order

MELBOURNE, Australia (14 May 2025) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has received a purchase order, and shipped the product today, for FebriDx from iMedical, Inc. for US\$126,000, which represents the largest single purchase order since the test’s launch and signals an increase in US customer adoption as well as continued market acceptance of the novel point-of-care test, FebriDx.

FebriDx is a rapid point-of-care respiratory test which delivers results in around 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.

iMedical is a leader in developing and delivering innovative cost-savings solutions tailored for hospitals, surgery centers, clinics, and healthcare facilities nationwide across the US. The company empowers its customers by significantly reducing operating expenses with high value services and products, like FebriDx, enabling them to optimize their annual budgets effectively. In addition, iMedical is fully dedicated to helping organizations improve overall efficiency through strategic access to premier services.

Commenting on the announcement, Dave Berthold, CEO of iMedical, Inc. said: *“We are excited to partner with Lumos Diagnostics to bring innovative diagnostic solutions to healthcare providers and patients. This collaboration reflects our shared commitment to advancing point-of-care technology and improving health outcomes across the continuum of care.”*

“I’m pleased to see FebriDx gaining traction and acceptance in the market,” said Doug Ward, CEO and Managing Director of Lumos Diagnostics. *“It’s a testament to the product’s clinical value and growing demand. Lumos looks forward to working more closely with iMedical to expand FebriDx’s market acceptance and adoption.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
HACK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

George Kopsiaftis
IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598